Cara Therapeutics discontinues study on a neurological condition as drug fails

(Reuters) – Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.

(Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)